Multiparametric Mapping of Knee Joint with Magnetic Resonance Fingerprinting

项目摘要 骨关节炎（OA）是一种退行性关节疾病，在美国影响超过2700万人 一个人这一庞大的受影响人群和随之而来的严重的OA衰弱导致了巨大的费用， 医疗保健系统。OA的特征在于生物化学、结构和形态降解， 关节软骨的细胞外基质（ECM）成分。ECM主要由两个组组成 包括蛋白聚糖（PG）和胶原纤维的大分子。软骨退变的早期诊断 需要能够非侵入性地检测PG浓度和胶原完整性的变化， 发生形态学变化。T1、T2和T1ρ弛豫时间受这些病理过程的影响， 是全世界使用最广泛的生化软骨MRI序列。 该提案的总体目标是开发、优化和翻译磁共振指纹识别技术， (MRF)框架，它允许同时，形态，体积和定量多参数 在短得多的时间（≤10分钟）内将[T1、T2、T1ρ、B1+和质子密度（PD）]映射到膝关节， 标准3 T临床扫描仪上的常规个体参数标测。基于MRF的 多参数映射方法可以很容易地纳入常规研究/临床协议， 膝关节的组织评估没有外源性造影剂，可以作为未来的成像 用于OA的疾病修饰疗法的生物标志物。

PROJECT SUMMARY Osteoarthritis (OA) is a degenerative joint disease, affecting more than 27 million people in the United States alone. This large affected population and the severe consequent debility of OA lead to significant expenses to the health care system. OA is characterized by biochemical, structural and morphologic degradation of components of the extracellular matrix (ECM) of articular cartilage. The ECM is composed of primarily two groups of macromolecules including proteoglycan (PG) and collagen fibers. Early diagnosis of cartilage degeneration would require the ability to non-invasively detect changes in PG concentration and collagen integrity before morphological changes occur. T1, T2 and T1ρ relaxation times are affected by these pathological processes and are the most widely used biochemical cartilage MRI sequences worldwide. The overarching goal of this proposal is to develop, optimize, and translate the magnetic resonance fingerprinting (MRF) framework, which allows for simultaneous, morphological, volumetric, and quantitative multiparametric mapping [T1, T2, T1ρ, B1+ and proton density (PD)] to the knee joint in a much shorter time (≤10 minutes) than conventional individual parametric mapping on a standard 3T clinical scanner. The proposed MRF-based multiparametric mapping approach can be easily incorporated into routine research/clinical protocols for multi- tissue assessment of the knee joint without exogenous contrast agents and could serve as future imaging biomarkers for disease modifying therapies for OA.